日祥應邀參加第八屆中國藥業研發國際峰會
第八屆中國藥業研發國際峰會於2013年5月在上海召開。
此高峰會主要由臨床與監管峰會、新藥開發及臨床前試驗會議、物製藥與生物仿製藥會議組成。並由國內外生物製藥、CRO、生物科技等相關領域公司提供演講及展覽，演講主題包含臨床實驗相關課題、法律規範最新趨勢，或新藥開發等議題。
日祥榮幸受邀以生物標記發展：New biomarker development: co-validation clinical trial in Taiwan and China為主題進行演講，並在會後與各國際藥物研發公司討論甲基化生物標記(methylation marker)在新藥開發之重要性。
|
|
iStat Biomedical presents data at the 8th Chinese pharmaceutical Research and Development International Summit |
iStat Biomedical is invited to present clinical study outcomes under the topic of "New biomarker development: co-validation clinical trial in Taiwan and China" at the 8th China Pharmaceutical Research and Development International Summit held in Shanghai, China on May 2013. Through the topic, we would share the experience of developing methylation marker for diagnostics purposes.
The summit comprised of multidisciplinary conferences including clinical, regulation, new drug development, preclinical studies, pharmaceutical and biosimilar. Global and domestic companies in the fields of biopharmaceuticals, CROs, biotechnology will provide speeches and exhibitions. The topics include clinical trials, the latest trends in legal regulations, and new drug development.
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518
第八屆中國藥業研發國際峰會於2013年5月在上海召開。
此高峰會主要由臨床與監管峰會、新藥開發及臨床前試驗會議、物製藥與生物仿製藥會議組成。並由國內外生物製藥、CRO、生物科技等相關領域公司提供演講及展覽，演講主題包含臨床實驗相關課題、法律規範最新趨勢，或新藥開發等議題。
日祥榮幸受邀以生物標記發展：New biomarker development: co-validation clinical trial in Taiwan and China為主題進行演講，並在會後與各國際藥物研發公司討論甲基化生物標記(methylation marker)在新藥開發之重要性。
|
|
iStat Biomedical presents data at the 8th Chinese pharmaceutical Research and Development International Summit |
iStat Biomedical is invited to present clinical study outcomes under the topic of "New biomarker development: co-validation clinical trial in Taiwan and China" at the 8th China Pharmaceutical Research and Development International Summit held in Shanghai, China on May 2013. Through the topic, we would share the experience of developing methylation marker for diagnostics purposes.
The summit comprised of multidisciplinary conferences including clinical, regulation, new drug development, preclinical studies, pharmaceutical and biosimilar. Global and domestic companies in the fields of biopharmaceuticals, CROs, biotechnology will provide speeches and exhibitions. The topics include clinical trials, the latest trends in legal regulations, and new drug development.
For more information, please visit: https://tw.epigenebio.com/
About iStat Biomedical
iStat Biomedical is a Taiwan-based biotechnology company specialized in the development and manufacturing of gene methylation assay IVD products for the early detection of cancers. iStat Biomedical develops innovative products that are primarily used in the clinical laboratories, and provides physicians with alternative solutions for clinical managements. iStat Biomedical also provides services for gene methylation detection and IVD contract manufacturing.
iStat Biomedical Co., Ltd contact:
+886-2-26963518